ANI Pharmaceuticals | ANIP - Sales Revenues


ANI Pharmaceuticals reported $237.5M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
Canopy Growth CAD 74.54M 7.86M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 750M Mar/2026
Perrigo USD 969M 141M Mar/2026
Sun Pharmaceuticals INR 145.86B 2.13B Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026